Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Intervalo de año de publicación
1.
J Child Adolesc Psychopharmacol ; 29(1): 20-27, 2019 02.
Artículo en Inglés | MEDLINE | ID: mdl-30388037

RESUMEN

OBJECTIVE: The aim of this pilot study was to explore the feasibility and proof of concept of triple chronotherapy (TCT) as a nonpharmacological adjunctive treatment in the acute management of depression in the adolescent population. METHODS: Thirty-one adolescents with nonpsychotic moderate-to-severe depression were included in the study. The 4-day TCT intervention comprised one night of sleep deprivation followed by 3 days of sleep phase advancement and daily bright light therapy. Primary outcomes were feasibility and depression, as measured by the Hamilton Depression Scale-17 (HAMD-17). Secondary outcomes included severity of illness, anxiety, self-harm, insomnia, and suicidality. RESULTS: Twenty-nine (94%) adolescents completed the 4-day TCT intervention. Twenty-six (84%) of the 31 enrolled patients experienced a reduction in depressive symptoms of at least 50% from baseline; 24 (77%) achieved remission, defined as a HAMD-17 score less than 8. The mean depression score was severe before the start of the intervention ( \documentclass{aastex}\usepackage{amsbsy}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{bm}\usepackage{mathrsfs}\usepackage{pifont}\usepackage{stmaryrd}\usepackage{textcomp}\usepackage{portland, xspace}\usepackage{amsmath, amsxtra}\usepackage{upgreek}\pagestyle{empty}\DeclareMathSizes{10}{9}{7}{6}\begin{document} $$\overline X$$ \end{document} = 21.8 ± 3.8) and dropped below the remission threshold by day 4 ( \documentclass{aastex}\usepackage{amsbsy}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{bm}\usepackage{mathrsfs}\usepackage{pifont}\usepackage{stmaryrd}\usepackage{textcomp}\usepackage{portland, xspace}\usepackage{amsmath, amsxtra}\usepackage{upgreek}\pagestyle{empty}\DeclareMathSizes{10}{9}{7}{6}\begin{document} $$\overline X$$ \end{document} = 4.4 ± 5.1; p < 0.001); the mean depression score was mild at 1 week (n = 17; \documentclass{aastex}\usepackage{amsbsy}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{bm}\usepackage{mathrsfs}\usepackage{pifont}\usepackage{stmaryrd}\usepackage{textcomp}\usepackage{portland, xspace}\usepackage{amsmath, amsxtra}\usepackage{upgreek}\pagestyle{empty}\DeclareMathSizes{10}{9}{7}{6}\begin{document} $$\overline X$$ \end{document} = 9.3 ± 5.2; p < 0.001) and 1 month (n = 10, \documentclass{aastex}\usepackage{amsbsy}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{bm}\usepackage{mathrsfs}\usepackage{pifont}\usepackage{stmaryrd}\usepackage{textcomp}\usepackage{portland, xspace}\usepackage{amsmath, amsxtra}\usepackage{upgreek}\pagestyle{empty}\DeclareMathSizes{10}{9}{7}{6}\begin{document} $$\overline X$$ \end{document} = 7.8 ± 5.2; p < 0.001). Severity of illness scores according to the Clinical Global Impressions severity subscale improved from a mean of 5.3 at baseline to 3.1 following the TCT intervention (p < 0.0001); the effect was sustained through the 1-week postdischarge and the 1-month follow-up. Secondary outcomes showed significant improvement following the 4-day TCT intervention; improvement was sustained through the 1-week and 1-month follow-up periods. CONCLUSIONS: This pilot study determined TCT to be a feasible, safe, rapid, and potentially effective adjunctive treatment for depression in the adolescent population.


Asunto(s)
Cronoterapia , Depresión/terapia , Fototerapia , Privación de Sueño , Adolescente , Ansiedad/psicología , Depresión/psicología , Femenino , Humanos , Pacientes Internos/estadística & datos numéricos , Masculino , Proyectos Piloto , Estudios Prospectivos , Escalas de Valoración Psiquiátrica/estadística & datos numéricos , Trastornos del Sueño-Vigilia
2.
Int J Oral Maxillofac Implants ; 33(6): 1362-1367, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30427968

RESUMEN

PURPOSE: This study evaluated the effect of the level of the prosthetic construction on the marginal bone stability around extra-short implants (≤ 6.5 mm in length) supporting a fixed prosthesis. MATERIALS AND METHODS: This retrospective study was performed at a private dental clinic. The patient charts were reviewed to select those who had an extra-short implant (≤ 6.5 mm in length) supporting a fixed prosthesis. A transmucosal abutment (transepithelial Multi-Im, BTI Biotechnology Institute) was used in those implants that were restored at the gingival level. Otherwise, the implants were restored at the platform level. Demographic data and implant-related and prosthesis-related variables were obtained. RESULTS: Thirty-three extra-short implants in 17 patients were assessed. The patients' mean age was 61 ± 12 years at the time of surgery. The prosthetic reconstruction was done at the platform level in 18 implants and at the gingival level (via transmucosal abutment) in 15 implants. Considering the use or not of a transmucosal abutment, there were no statistically significant differences in all studied variables except bone stability. The extra-short implants that were restored at the platform level experienced more crestal bone loss (P = .024). CONCLUSION: The extra-short implant restoration at the gingival level would increase the stability of the marginal bone.


Asunto(s)
Pérdida de Hueso Alveolar/cirugía , Pilares Dentales , Implantes Dentales , Prótesis Dental de Soporte Implantado , Adulto , Anciano , Anciano de 80 o más Años , Pérdida de Hueso Alveolar/diagnóstico por imagen , Diseño de Implante Dental-Pilar , Técnica de Impresión Dental , Diseño de Prótesis Dental , Restauración Dental Provisional , Femenino , Humanos , Masculino , Persona de Mediana Edad , Radiografía Dental , Estudios Retrospectivos
3.
J Psychiatr Res ; 62: 14-22, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25669696

RESUMEN

BACKGROUND: Serum levels of the astrocytic protein S100B have been reported to indicate disruption of the blood-brain barrier. In this study, we investigated the relationship between S100B levels and childhood trauma in a child psychiatric inpatient unit. METHOD: Levels of S100B were measured in a group of youth with mood disorders or psychosis with and without history of childhood trauma as well as in healthy controls. Study participants were 93 inpatient adolescents admitted with a diagnosis of psychosis (N = 67), or mood disorder (N = 26) and 22 healthy adolescents with no history of trauma or psychiatric illness. Childhood trauma was documented using the Life Events Checklist (LEC) and Adverse Child Experiences (ACE). RESULTS: In a multivariate regression model, suicidality scores and trauma were the only two variables which were independently related to serum S100B levels. Patients with greater levels of childhood trauma had significantly higher S100B levels even after controlling for intensity of suicidal ideation. Patients with psychotic diagnoses and mood disorders did not significantly differ in their levels of S100B. Patients exposed to childhood trauma were significantly more likely to have elevated levels of S100B (p < .001) than patients without trauma, and patients with trauma had significantly higher S100B levels (p < .001) when compared to the control group. LEC (p = 0.046), and BPRS-C suicidality scores (p = 0.001) significantly predicted S100B levels. CONCLUSIONS: Childhood trauma can potentially affect the integrity of the blood-brain barrier as indicated by associated increased S100B levels.


Asunto(s)
Subunidad beta de la Proteína de Unión al Calcio S100/sangre , Heridas y Lesiones/sangre , Adolescente , Niño , Femenino , Humanos , Pacientes Internos , Masculino , Trastornos del Humor/etiología , Análisis de Regresión , Ideación Suicida , Índices de Gravedad del Trauma , Heridas y Lesiones/complicaciones , Heridas y Lesiones/psicología
4.
Rev. chil. pediatr ; 85(5): 588-593, oct. 2014. tab
Artículo en Español | LILACS | ID: lil-731647

RESUMEN

Introduction: Dravet syndrome (DS) is one of the most intractable forms of epilepsy that begins in infancy. This syndrome is characterized by beginning with complex febrile seizures (FS) in a healthy infant and progresses to refractory epilepsy with psychomotor regression. The detection of a SCN1A mutation encoding the sodium channel can confirm the diagnosis. Objective: To report 3 confirmed cases of genetically DS. Case reports: We describe 3 girls diagnosed with complex FS that started when they were between 2 and 7 months old. FS were frequent, hemi generalized and myoclonic associated with recurrent febrile status epilepticus (SE). Despite FS and SE recurrence, the psychomotor development, electrophysiological studies and magnetic resonance imaging (MRI) of the brain were normal. After a year, they developed afebrile seizures progressing to refractory epilepsy with developmental regression. A molecular study detected SCN1A mutation confirming DS. The specific antiepileptic treatment and prevention of febrile episodes allowed partial control of epilepsy with some recovery of psychomotor skills. Conclusions: The high frequency complex FS associated with recurrent SE in a previously healthy infant should alert about the possibility of DS. Molecular diagnostics helps us to establish a drugs and non-drug therapies treatment, as well as long-term prognosis and genetic counseling.


Introducción: El Síndrome de Dravet (SD) es una de las formas más intratables de epilepsia que debuta en lactantes con convulsiones febriles (CF) complejas recurrentes que evolucionan posteriormente a epilepsia refractaria con regresión psicomotora. La detección de una mutación del canal de Sodio (SCN1A) permite certificar el diagnóstico. Objetivo: Reportar 3 casos de SD confirmados genéticamente. Casos clínicos: Se describen 3 niñas con diagnóstico de CF complejas iniciadas entre los 2 y 7 meses de edad. Las CF eran frecuentes, hemigeneralizadas, mioclónicas asociadas a status epilepticus (SE) febriles recurrentes. A pesar de la recurrencia de CF y SE, tanto el desarrollo psicomotor como los estudios electrofisiológicos y la resonancia magnética (RM) cerebral, fueron normales. Posterior al año iniciaron crisis afebriles que evolucionaron a epilepsia refractaria con regresión del desarrollo. El estudio molecular detectó la mutación SCN1A confirmando SD. El tratamiento antiepiléptico específico y la prevención de cuadros febriles permitieron un control parcial de la epilepsia con recuperación de algunas habilidades psicomotoras. Conclusiones: La alta frecuencia de CF complejas asociadas a SE recurrentes en un lactante previamente sano, debe alertar sobre la posibilidad de un SD. El diagnóstico molecular nos permite instaurar un tratamiento antiepiléptico y terapias no farmacológicas además de un pronóstico a largo plazo y consejería genética.


Asunto(s)
Niño , Preescolar , Femenino , Humanos , Lactante , Anticonvulsivantes/uso terapéutico , Epilepsias Mioclónicas/diagnóstico , Canal de Sodio Activado por Voltaje NAV1.1/genética , Convulsiones Febriles/diagnóstico , Epilepsias Mioclónicas/tratamiento farmacológico , Epilepsias Mioclónicas/genética , Imagen por Resonancia Magnética , Mutación , Estado Epiléptico/diagnóstico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA